Related Experiment Video
Updated: Dec 21, 2025
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.6K
Headache attributed to craniocervical dystonia: A prospective cohort study
Marcos Eugenio Ramalho Bezerra1, Pedro A Sampaio Rocha-Filho2,3
1Hospital das Clínicas, Universidade Federal de Pernambuco (UFPE), Recife, Brazil.
European Journal of Pain (London, England)
|May 19, 2020
Summary
Headaches are common in cervical dystonia patients, impacting quality of life. Botulinum toxin type-A (BoNT-A) injections significantly improve these headaches and dystonia symptoms, contrary to previous assumptions.
Area of Science:
- Neurology
- Pain Medicine
- Movement Disorders
Background:
- Cervical dystonia (CD) is a common focal dystonia often linked to pain.
- Headaches are not typically considered prevalent in CD patients.
- Headaches attributed to craniocervical dystonia are poorly understood and considered rare.
Purpose of the Study:
- To determine the prevalence and characteristics of headaches in CD patients.
- To assess the impact of headaches on quality of life.
- To evaluate the effect of botulinum toxin type-A (BoNT-A) on headaches in CD.
Main Methods:
- 24 CD patients were assessed before and after BoNT-A treatment.
- Headache classification followed the International Classification of Headache Disorders.
- Validated questionnaires measured pain, disability, anxiety, and depression.
Main Results:
- 75% of CD patients experienced headaches, with a 29.2% prevalence of headaches attributed to craniocervical dystonia.
- Patients with headaches had significantly higher pain scores and disability.
- BoNT-A treatment improved headache impact and dystonia symptoms.
Conclusions:
- Headaches are highly prevalent in cervical dystonia patients.
- These headaches negatively impact quality of life.
- BoNT-A treatment offers significant relief for headaches and improves overall symptoms in CD.
